India
· Delayed Price · Currency is INR AKUMS Statistics
Total Valuation
Akums Drugs and Pharmaceuticals has a market cap or net worth of INR 100.75 billion. The enterprise value is 98.24 billion.
| Market Cap | 100.75B |
| Enterprise Value | 98.24B |
Important Dates
The last earnings date was Friday, November 22, 2024.
| Earnings Date | Nov 22, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Akums Drugs and Pharmaceuticals has 157.39 million shares outstanding. The number of shares has increased by 1.06% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 157.39M |
| Shares Change (YoY) | +1.06% |
| Shares Change (QoQ) | +4.40% |
| Owned by Insiders (%) | 34.50% |
| Owned by Institutions (%) | 7.84% |
| Float | 27.32M |
Valuation Ratios
The trailing PE ratio is 33.32.
| PE Ratio | 33.32 |
| Forward PE | n/a |
| PS Ratio | 2.27 |
| PB Ratio | 3.37 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 55.22 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.95, with an EV/FCF ratio of 53.84.
| EV / Earnings | 35.37 |
| EV / Sales | 2.41 |
| EV / EBITDA | 21.95 |
| EV / EBIT | 31.15 |
| EV / FCF | 53.84 |
Financial Position
The company has a current ratio of 2.13, with a Debt / Equity ratio of 0.19.
| Current Ratio | 2.13 |
| Quick Ratio | 1.42 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | 1.18 |
| Debt / FCF | 2.91 |
| Interest Coverage | 6.39 |
Financial Efficiency
Return on equity (ROE) is 16.60% and return on invested capital (ROIC) is 8.33%.
| Return on Equity (ROE) | 16.60% |
| Return on Assets (ROA) | 5.01% |
| Return on Capital (ROIC) | 8.33% |
| Revenue Per Employee | 5.53M |
| Profits Per Employee | 375,960 |
| Employee Count | 7,388 |
| Asset Turnover | 1.04 |
| Inventory Turnover | 3.73 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 821.83 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 34.54 |
| Average Volume (20 Days) | 339,974 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Akums Drugs and Pharmaceuticals had revenue of INR 40.83 billion and earned 2.78 billion in profits. Earnings per share was 19.21.
| Revenue | 40.83B |
| Gross Profit | 15.66B |
| Operating Income | 3.15B |
| Pretax Income | 2.05B |
| Net Income | 2.78B |
| EBITDA | 4.38B |
| EBIT | 3.15B |
| Earnings Per Share (EPS) | 19.21 |
Balance Sheet
The company has 7.95 billion in cash and 5.30 billion in debt, giving a net cash position of 2.65 billion or 16.81 per share.
| Cash & Cash Equivalents | 7.95B |
| Total Debt | 5.30B |
| Net Cash | 2.65B |
| Net Cash Per Share | 16.81 |
| Equity (Book Value) | 28.47B |
| Book Value Per Share | 189.90 |
| Working Capital | 13.91B |
Cash Flow
In the last 12 months, operating cash flow was 5.06 billion and capital expenditures -3.23 billion, giving a free cash flow of 1.82 billion.
| Operating Cash Flow | 5.06B |
| Capital Expenditures | -3.23B |
| Free Cash Flow | 1.82B |
| FCF Per Share | 11.59 |
Margins
Gross margin is 38.35%, with operating and profit margins of 7.72% and 6.80%.
| Gross Margin | 38.35% |
| Operating Margin | 7.72% |
| Pretax Margin | 5.03% |
| Profit Margin | 6.80% |
| EBITDA Margin | 10.74% |
| EBIT Margin | 7.72% |
| FCF Margin | 4.47% |
Dividends & Yields
Akums Drugs and Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.06% |
| Shareholder Yield | -1.06% |
| Earnings Yield | 3.00% |
| FCF Yield | 1.81% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |